In fall of 2016 when Open Therapeutics launches and makes freely available to the global scientific community its biopharmaceutical platform technologies via the Open Therapeutics™ crowd-sourcing web portal, it will begin a new era in shared research, promising new therapies for cancer. As it is now, independent research is conducted in a closed environment fueled by stakeholders who profit in having their researchers sign non-disclosure agreements and forbid them to share research. This effectively puts control of innovative therapies and the resulting drugs out of reach, either by cost or geography, of those who need them most.
Many patients don’t have access to breakthrough therapies, either because they can’t afford to travel to hospitals offering the latest and best or because they lack information about their options.
Jason Barkeloo, founder of Open Therapeutics, reminds us that, even if a patient can gain the travel visa, afford the travel and treatment cost, traveling for immune-compromised individuals is problematic:
“There can be…health complications that preclude travel, and…time is never on the side of the patient. Open technologies should produce local economic developments, for example, value at the edge of the network, within the boundaries of their own legal and regulatory structures. This should reduce such extreme travel distances and associated costs.”
Open Therapeutics is an agnostic web portal service that reduces the cost and risk of developing and deploying therapeutics. By stimulating an economies of scale model and micro-pharma indigenous industries, the global population should experience lower prices and greater availability of life-saving drugs. While crowd-sourcing scientists around open biopharma technologies designed to enhance health, Open Therapeutics collects and enhances important research, including clinical and interactive data.